US Stock Market Movement: Guardant Health Plunges on October 6 due to Intensified Competition, Cash Flow Pressure, and Internal Sell-offs

Guardant Health October 6 Major Drop Analysis

Keywords: intensified competition, cash flow pressure, insider selling

1. On September 30, 2026, Abbott launched Freenome's SimpleScreen blood-based colorectal cancer screening test in the United States, creating competition with Guardant Health's Shield product. Industry competition has intensified.

2. On October 5, 2026, institutional analysis pointed out that the company continues to generate negative free cash flow, revenue remains relatively small, and profitability still faces pressure, with fundamental risks drawing attention.

3. From September 15 to 16, 2026, the company's Chief Technology Officer and directors collectively sold Guardant Health shares, with increased insider selling adding short-term supply pressure.

(Disclaimer: This content is generated by AI technology based on publicly available information for summary purposes only. It does not constitute investment advice.)